Drug intelligence / Profile preview

verenafusp alfa

Development stage: Phase 3
Lead developer: AO GENERIUM
Modality: Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

Verenafusp alfa is a recombinant fusion protein that functions as an anti-insulin receptor (INSR) antibody. It is designed to target the insulin receptor, potentially modulating insulin signaling pathways. The drug's mechanism of action and clinical development status are not well-documented in public sources, and there is limited information available regarding its indications, developer, or clinical trial progress[10]. No evidence was found linking verenafusp alfa to any specific disease area or confirming its use in clinical trials.

Brand names: Clotilia
Other names: verenafusp alfa

Targets

HS (Heparan sulfate)INSR (Insulin receptor)

Beyond the preview

Go deeper on verenafusp alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on verenafusp alfa.

Explore the full profile